Skip to content

Category: Technology & Research

Acucela Initiates Phase 2a Study of Emixustat Hydrochloride Addressing Patients with Stargardt Disease

Posted in Technology & Research

SEATTLE (January 26, 2017) — Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide, announced today that on January 25, 2017, the first patient has enrolled in a study to evaluate Acucela’s leading drug candidate, emixustat hydrochloride (“emixustat”) in subjects with macular atrophy secondary to Stargardt disease.

Via degli Dei: when a sensory journey becomes an emotional journey

Posted in Technology & Research

Like an alchemist, Nadia knows how to distill the emotions that the passageway, la Via degli Dei, intended. She has the capacity to write what others only know how to feel and experience. Being visually impaired has a lot to do with this. To be able to read and then translate, to be able to translate senses felt only with the heart. And yet she wonders whether it is possible to draw an emotional map that gives answers.